Language
English
Publication Date
12-1-2023
Journal
Hematology/Oncology Clinics of North America
DOI
10.1016/j.hoc.2023.05.017
PMID
37357070
PMCID
PMC10697615
PubMedCentral® Posted Date
12-1-2024
PubMedCentral® Full Text Version
Author MSS
Abstract
The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting the unique challenges of their use in this subset of lymphomas. Furthermore, the authors present future directions and ongoing trials investigating the use of CAR-T cells in TCL and HL.
Keywords
Humans, Receptors, Chimeric Antigen, Ki-1 Antigen, Lymphoma, Hodgkin Disease, Lymphoma, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell
Published Open-Access
yes
Recommended Citation
, "Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas" (2023). Faculty, Staff and Students Publications. 1568.
https://digitalcommons.library.tmc.edu/baylor_docs/1568